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Since the rosiglitazone controversy aroused in 2007 [1], US 
Food and Drug Administration and most other regulatory 
agencies have requested to perform cardiovascular safety as-
sessments for upcoming antidiabetic medications [2]. Dipep-
tidyl peptidase-4 (DPP4) inhibitors belong to a new class of 
oral antidiabetic drugs which can ameliorate hyperglycemia 
by increasing endogenous concentration of glucagon-like pep-
tide-1, a gut-derived hormone that stimulates insulin secretion 
and delays gastric emptying. However, despite its popularity in 
the diabetes market, the cardiovascular safety of DPP4 inhibi-
tors has not been investigated following the two large, ran-
domized, placebo-controlled trials (RCTs), saxagliptin assess-
ment of vascular outcomes recorded in patients with diabetes 
mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 
53) [3] with saxagliptin and Examination  of  Cardiovascular 
Outcomes  with Alogliptin vs. Standard of Care (EXAMINE) 
[4] with alogliptin, which recently published the results of car-
diovascular outcomes in 2013. 
 Unexpectedly, SAVOR-TIMI 53 showed that the rate of hos-
pital admission for heart failure was significantly increased by 
27% in subjects treated with saxagliptin, while EXAMINE did 
not report any outcome related to heart failure. A subsequent 
paper based on EXAMINE trial reported that alogliptin was 
not associated with the increased risk of heart failure outcomes, 
such as hospital admission for heart failure, compared with pla-
cebo group [5]. However, both studies observed that hospital 
admission for heart failure occurred more frequently in sub-
jects treated with saxagliptin or alogliptin who had no history 
of this disease condition (SAVOR-TIMI 53: hazard ratio [HR], 
1.30, 95% confidence interval [CI], 1.03 to 1.65; EXAMINE: 
HR, 1.76, 95% CI, 1.07 to 2.90). According to the additional re-
port from SAVOR-TIMI 53, the high-risk patients for heart 
failure hospitalization were those who had a prior history of 
heart failure, elevated baseline levels of N-terminal pro-brain 
natriuretic peptide, or chronic kidney disease [6]. 
 To date, several studies demonstrated conflicting results re-
garding the safety of DPP4 inhibitors on heart failure. A nested 
case-control study based on a large insurance claimed that the 
database from United States showed that sitagliptin was associ-
ated with heart failure admissions in patients recently diag-
nosed with heart failure (adjusted odds ratio [OR], 1.84; 95% 
CI, 1.16 to 2.92; P=0.01) [7]. A propensity-matched analysis 
using Taiwan National Health Insurance research database 
with a total of 16,576 subjects reported that sitagliptin users 
were hospitalized for heart failure more frequently than pa-
tients that were never exposed to a DPP4 inhibitor (HR, 1.21; 
95% CI, 1.04 to 1.42; P=0.017) [8]. In this study, patients with 
the highest adherence to sitagliptin had the greatest risk of de-
veloping heart failure (HR, 2.56; 95% CI, 2.10 to 3.12) com-
pared with never users. In addition, similar findings were de-
rived from a recent meta-analysis of 82 randomized controlled 
clinical trials with various DPP4 inhibitors treated for at least 
24 weeks. The overall risk of acute heart failure was significant-
ly elevated in the DPP4 inhibitor group compared with place-
bo/active comparators (n=69,615; Mantel-Haenszel OR, 1.19; 
95% CI, 1.03 to 1.37; P=0.015) [9]. In Vildagliptin in Ventricu-
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lar Dysfunction Diabetes (VIVIDD) trial, 254 subjects with 
type 2 diabetes and New York Heart Association functional 
classes I through III heart failure were randomized to vilda-
gliptin or placebo for 12 months [10]. Although there was no 
difference in left ventricular ejection fraction between two 
groups, patients treated with vildagliptin had an increase in left 
ventricular end-diastolic volumes, suggesting that vildagliptin 
could possibly increase the risk of heart failure.
 However, a recent population-based study from United King-
dom showed that incretin-based drugs were not associated with 
an increased risk of heart failure among patients with type 2 dia-
betes (OR, 0.85; 95% CI, 0.62 to 1.16) [11]. Although five drugs 
(sitagliptin, vildagliptin, saxagliptin, exenatide, and liraglutide) 
were included in the analysis, majority of patients were pre-
scribed sitagliptin. A non-randomized, observational real-world 
study from Germany (DiaRegis registry) enrolled patients with 
prior metformin monotherapy who then received either DPP4 
inhibitors or sulfonylurea [12]. Similarly, there was no differ-
ence in event rates of heart failure between two groups (1.7% in 
the DPP4 inhibitor group vs. 2.0% in the sulfonylurea group, 
P=0.85), while subjects with DPP4 inhibitors showed signifi-
cantly lower rates of stroke and transitory ischemic attack.  
 In this issue of Diabetes and Metabolism Journal, Seo et al. 
[13] provided additional concerns about the safety of DPP4 
inhibitors on heart failure in Korean type 2 diabetes. Based on 
Korean Health Insurance claims database, they used piogli-
tazone as a positive control for increasing risk of heart failure 
[14] and compared the incidence rate of hospital admission 
for heart failure with DPP4 inhibitors. Compared with piogli-
tazone group, sitagliptin and vildagliptin users did not show 
any significant difference in hospitalization rate for heart fail-
ure, indicating the comparable effects on the development of 
heart failure between DPP4 inhibitors and pioglitazone. De-
spite the large number of subjects, the potential for confound-
ing in this study cannot be ruled out because of the limitation 
of the nature of claim database. Furthermore, there is no infor-
mation regarding compliance of medications and comorbidi-
ties in the study population which should be adjusted in the 
analysis. Regardless of drug types, the hospitalization rate for 
heart failure was greatest in the first 30 days after starting to 
take the medication, when compared with days 31 to 360 days. 
Similar to their findings, Scirica et al. [6] reported that the risk 
of heart failure hospitalization was most pronounced in the 
first 12 months of treatment with saxagliptin. These two find-
ings suggest that DPP4 inhibitors may trigger heart failure in 
vulnerable but unidentified or subclinical subjects who are 
likely to develop heart failure. On the contrary to thiazolidine-
diones, DPP4 inhibitors are not associated with edema or fluid 
retention, therefore the mechanism for heart failure might be 
different, which should be elucidated by further research.
 In summary, inconsistent findings from various studies, in-
cluding meta-analyses, large randomized trials, observational 
studies, and analysis of insurance claim database, indicate that 
we still cannot draw any definite conclusion in terms of the 
safety of DPP4 inhibitors on heart failure in patients with type 
2 diabetes. We should wait with prudence for the upcoming re-
ports from Trial Evaluating Cardiovascular Outcomes with Si-
tagliptin (TECOS) trial [15], another large RCT with Sitagliptin 
including 14,724 subjects with type 2 diabetes and Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results (LEADER) trial [16], to fully address all the 
concerns related to the safety issues of incretin-based drugs on 
heart failure. 
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